Stocktoria
Sun Pharmaceutical Industries Limited SUNPHARMA.NS
Sun Pharmaceutical Industries Limited statistics & valuation
Multiples are price-derived and refreshed daily; everything else from the latest financial reports. The Graham number is Benjamin Graham's rough maximum fair value (₹612.05); a green figure means the price is below it.
Profitability & efficiency
Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).
P / E vs its own history
Sun Pharmaceutical Industries Limited trades at about 40.3× earnings — near its 10-year norm (10-year range 28×–40.2×, median 37.8×).
Shaded band = 10-year range (28×–40.2×); dot = today's 40.3×.
Historical P/E = month-end price near each fiscal year-end ÷ that year's EPS. A read on whether the stock is cheap or dear relative to how it has typically been valued — not a forecast.
Key ratios (by fiscal year)
| Ratio | FY2026 | FY2025 | FY2024 | FY2023 |
|---|---|---|---|---|
| Gross margin | 77.4% | 76.6% | 74.7% | 72.4% |
| Operating margin | 23.4% | 24.2% | 21.9% | 21.4% |
| Net margin | 19.7% | 21.0% | 20.1% | 19.6% |
| FCF margin | 15.1% | 23.0% | 20.8% | 6.6% |
| Return on assets | 10.6% | 11.9% | 11.2% | 10.5% |
| Return on equity | 13.7% | 15.1% | 15.0% | 15.1% |
| Debt / equity | 0.00× | 0.00× | 0.00× | 0.00× |
| Current ratio | 2.82 | 2.89 | 2.56 | 2.00 |
Computed from company filings · IN · as of 2026-03-31. Figures in INR. Facts plus Stocktoria's own computed scores — not investment advice.